Table 1 Patient characteristic in intervention groups
Follow-up group, n = 63 | Fluid bolus group, n = 67 | |
|---|---|---|
Age (years) | 67 [53–72] | 69 [59–76] |
Sex; female (%) | 19 (30.2) | 26 (38.8) |
Weight (kg) | 85 [75–102] | 83 [73–100] |
Hypertension (%) | 37 (58.7) | 44 (65.7) |
Chronic heart failure (%) | 1 (1.6) | 2 (3.0) |
Atrial fibrillation (%) | 9 (14.3) | 14 (20.9) |
Coronary artery disease (%) | 4 (6.3) | 7 (10.4) |
Arteriosclerosis obliterans (%) | 4 (6.3) | 5 (7.5) |
Chronic obstructive pulmonary disease (%) | 5 (7.9) | 4 (6.0) |
Chronic liver insufficiency (%) | 2 (3.2) | 0 (0.0) |
Diabetes (%) | 13 (20.6) | 22 (32.8) |
Malignancy (%) | 12 (19.0) | 9 (13.4) |
Rheumatoid disease (%) | 4 (6.3) | 4 (6.0) |
SAPS II score | 37 [34–45] | 41 [33–48] |
Surgical admission (%) | 33 (52.4) | 37 (55.2) |
At randomization | ||
Time from ICU admission to randomization (hours) | 18.8 [11.1–29.2] | 20.2 [12.5–35.2] |
Sepsis (%) | 35 (55.6) | 37 (55.2) |
Acute kidney injury (%) | 37 (58.7) | 40 (59.7) |
Acute kidney injury stage 1 (%)* | 19 (51.4) | 25 (62.5) |
Acute kidney injury stage 2 (%)* | 11 (29.7) | 11 (27.5) |
Acute kidney injury stage 3 (%)* | 7 (18.9) | 4 (10.0) |
Invasive ventilation (%) | 33 (52.4) | 34 (50.7) |
Vasoactive medication (%)** | 30 (47.6) | 32 (47.8) |
Continuous sedation (%) | 33 (52.4) | 28 (41.8) |
Cumulative balance from ICU admission to randomization (mL) | 1856 [1296–2948] | 1941 [1201–3762] |
SOFA score at randomization (− 24 to 0 h) | 7 [6–10] | 7 [5–9] |
SOFA score 24 h post-randomization (0 to 24 h) | 7 [5–8]*** | 6 [3–9] |